Table of Contents 2
List of Tables 4
List of Figures 4
Pfenex Inc. Spshot 5
Pfenex Inc. Overview 5
Key Information 5
Key Facts 5
Pfenex Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Pfenex Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combition Treatment Modalities 11
Pfenex Inc. - Pipeline Products Glance 12
Pfenex Inc. - Clinical Stage Pipeline Products 12
Phase I Products/Combition Treatment Modalities 12
Pfenex Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combition Treatment Modalities 13
Pfenex Inc. - Drug Profiles 14
ranibizumab biosimilar 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
interferon beta-1b 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Px-563L 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
teriparatide biosimilar 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
certolizumab pegol biosimilar 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
pegaspargase biosimilar 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
pegfilgrastim 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
peginterferon alfa-2a 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
PF-726 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Px-533 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Px-563L Second Generation 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
somatropin 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Pfenex Inc. - Pipeline Alysis 27
Pfenex Inc. - Pipeline Products by Target 27
Pfenex Inc. - Pipeline Products by Route of Administration 28
Pfenex Inc. - Pipeline Products by Molecule Type 29
Pfenex Inc. - Pipeline Products by Mechanism of Action 30
Pfenex Inc. - Recent Pipeline Updates 31
Pfenex Inc. - Dormant Projects 33
Pfenex Inc. - Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 35
Disclaimer 36